Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment
Clinical Lymphoma and Myeloma , Volume 8 - Issue 6 p. 352- 355
A retrospective analysis was undertaken of patients (n = 193) with renal insufficiency (creatinine clearance [CrCl] < 60 mL/min) from a phase III trial comparing bortezomib ± pegylated liposomal doxorubicin (PLD) in relapsed/refractory myeloma (n = 646). The response rate (49% vs. 42%) and median time to disease progression (331 days vs. 199 days) were comparable or slightly better for patients with renal insufficiency treated with PLD/bortezomib compared with patients treated with bortezomib alone. There was a steady, clinically meaningful improvement in renal function for patients with renal insufficiency in both treatment arms. However, patients with impaired renal function were at a slightly increased risk of a drug-related serious adverse event (28% vs. 19% for CrCl < 60 and ≥ 60 mL/min, respectively).
|Creatinine clearance, Paraprotein reduction, Thrombocytopenia|
|Clinical Lymphoma and Myeloma|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Bladé, J, Sonneveld, P, San Miguel, J.F, Sutherland, H, Hajek, R, Nagler, A, … Orlowski, R.Z. (2008). Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment. Clinical Lymphoma and Myeloma, 8(6), 352–355. doi:10.3816/CLM.2008.n.051